Striking the Right Balance With Prostate Cancer Screening.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Diagnostic Efficiency of Age-Adjusted PSAD for Prostate Cancer and Clinically Significant Prostate Cancer: Construction and Nomogram Validation.Journal of clinical laboratory analysis · 2026
   Article
2. Importance and implications of exosomes in nephrology and urology.Pflugers Archiv : European journal of physiology · 2023
   Review
3. Shifts in Chronic Disease Patterns Among Spanish Older Adults With Multimorbidity Between 2006 and 2017.International journal of public health · 2023
   Article
4. The Body Guidelines: A Metacognitive and Harm Reducing Approach to Gender and Sex in Preclinical Medical School Curriculum.Journal of medical education and curricular development
   Article

Corrections and comments

• Comment on
  Trends in Incidence of Metastatic Prostate Cancer in the US.2022

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as